EU Throws Weight Behind Pfizer/BioNTech and New Technology

EU Throws Weight Behind Pfizer/BioNTech and New Technology
European Commission President Ursula von der Leyen delivers a statement after a meeting of the college of commissioners at EU headquarters in Brussels, on April 14, 2021. John Thys/Pool via AP
|Updated:

BRUSSELS—In a stinging rebuke to pharma giant AstraZeneca on Wednesday, the European Union announced plans to negotiate a massive contract extension for Pfizer/BioNTech’s COVID-19 vaccine, insisting the 27-nation bloc had to go with companies that had shown their value in the pandemic.

“We need to focus on technologies that have proven their worth,” said EU Commission President Ursula von der Leyen. She also announced that America’s Pfizer and Germany’s BioNTech would provide the EU with an extra 50 million doses in the second quarter of this year, making up for faltering deliveries of AstraZeneca.